Technical Analysis for COLL - Collegium Pharmaceutical, Inc.
|Grade||Last Price||% Change||Price Change|
COLL closed up 1.46 percent on Wednesday, November 14, 2018, on 1.19 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Up||Up|
|See historical COLL trend table...|
|Date||Alert Name||Type||% Chg|
|Nov 14||Calm After Storm||Range Contraction||0.00%|
|Nov 14||NR7||Range Contraction||0.00%|
|Nov 14||Stochastic Reached Overbought||Strength||0.00%|
|Nov 14||Overbought Stochastic||Strength||0.00%|
|Nov 14||Up 3 Days in a Row||Strength||0.00%|
|Nov 14||Upper Bollinger Band Touch||Strength||0.00%|
|Nov 13||Crossed Above 20 DMA||Bullish||1.46%|
|Nov 13||Crossed Above 50 DMA||Bullish||1.46%|
|Nov 13||MACD Bullish Signal Line Cross||Bullish||1.46%|
|Nov 12||50 DMA Resistance||Bearish||9.78%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more COLL news...
|52 Week High||29.9|
|52 Week Low||13.7|
|200-Day Moving Average||21.1882|
|50-Day Moving Average||16.054|
|20-Day Moving Average||16.296|
|10-Day Moving Average||16.107|
|Average True Range||1.047|
|Chandelier Exit (Long, 3 ATRs )||14.699|
|Chandelier Exit (Short, 3 ATRs )||16.841|
|Upper Bollinger Band||17.4404|
|Lower Bollinger Band||15.1516|
|Percent B (%b)||0.98|
|MACD Signal Line||-0.0951|
|Market Cap||514.46 Million|
|Num Shares||29.6 Million|
|Price-to-Earnings (P/E) Ratio||-4.85|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||18.30|
|Resistance 3 (R3)||18.25||17.90||18.15|
|Resistance 2 (R2)||17.90||17.67||17.93||18.10|
|Resistance 1 (R1)||17.65||17.53||17.78||17.70||18.05|
|Support 1 (S1)||17.05||17.07||17.18||17.10||16.75|
|Support 2 (S2)||16.70||16.93||16.73||16.70|
|Support 3 (S3)||16.45||16.70||16.65|
|Support 4 (S4)||16.50|